Skip to main content
Log in

Wnt is back in drugmakers' sights, but is it druggable?

  • News
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Change history

  • 30 November 2018

    In the version of this article initially published, Table 1 listed SM04554 as a Wnt pathway inhibitor; in fact, it is a Wnt pathway activator. The error has been corrected in the HTML and PDF versions of the article.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sheridan, C. Wnt is back in drugmakers' sights, but is it druggable?. Nat Biotechnol 36, 1028–1029 (2018). https://doi.org/10.1038/nbt1118-1028

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1118-1028

  • Springer Nature America, Inc.

This article is cited by

Navigation